Virginia Tech
Repurposing a Kinase Inhibitor for Rift Valley Fever Virus: Combating Hepatic and Neurological Disease Through Antiviral and Immunomodulation Strategies
Abstract
dc:description.abstractRift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen endemic across the African continent. It represents a significant concern to local agriculture, veterinary and human health, also possessing great pandemic risk. Transmission occurs through infected mosquito vectors or direct exposure to contaminated animal tissues and fluids, disproportionately affecting individuals in close contact with livestock. Human infection is typically self-limiting, but severe manifestations include hepatitis, encephalitis, retinitis, and hemorrhagic disease. No approved antiviral therapeutics currently exist for RVFV infection. This dissertation investigated the role of host casein kinase 1 (CK1) in RVFV replication and NF-κB-mediated inflammation. CK1 regulates multiple cellular processes, including cell cycle progression, apoptosis, DNA damage repair, circadian rhythm, and immune signaling, making it a potential host-directed therapeutic target. Human lung, liver, and neural two-dimensional cell culture models were used to evaluate CK1 inhibition with BTX-A51. BTX-A51 treatment significantly reduced NF-κB-associated cytokines and inflammatory enzymes, while also demonstrating antiviral activity in monolayer cultures. Interactions between NF-κB and β-catenin signaling were additionally observed and discussed. These results were further tested in a human induced pluripotent stem cell (hiPSC)-derived cerebral organoid model. Cerebral organoids were permissive to RVFV infection, also exhibiting some NF-κB-mediated inflammation. BTX-A51 treatment attenuated inflammation while preserving interferon-α and β responses, although antiviral effects promoted by drug treatment in two-dimensional systems were not significant in organoids. Collectively, these findings identify CK1 as a potential host-directed target for immunomodulatory treatment of RVFV pathogenesis and support BTX-A51 as a repurposed therapeutic candidate. This work also demonstrates the value of cerebral organoids as translational models that may reduce reliance on animal studies.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Biomedical and Veterinary Sciences
- Department dc:contributor.department
- Biomedical and Veterinary Sciences
- Grantor dc:publisher
- Virginia Tech
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Machado Flor, Rafaela
- Chair dc:contributor.committeechair
-
- Kehn-Hall, Kylene Wesley
- Committee members dc:contributor.committeemember
-
- Auguste, Albert Jonathan
- Weger, James David
- Duggal, Nisha
Subjects
dc:subject × 4Rights
dc:rights- Statement dc:rights
-
- Creative Commons Attribution 4.0 International
- Licence dc:rights.uri
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Dc Identifier Other
- vt_gsexam:47030